Isolated liver perfusion for liver metastases: Pharmacokinetic advantage?

Surgical Oncology Clinics of North America

Volumn 5, Issue 2, 1996, Pages 443-449

  Ravikumar, T S ^a   Dixon, K ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN;

AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; HEPATIC ARTERY; HUMAN; INTRAARTERIAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LIVER CELL CARCINOMA; LIVER METASTASIS; LIVER PERFUSION; LIVER VEIN; REGIONAL PERFUSION;

EID: 0029880764     PISSN: 10553207     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1055-3207(18)30393-4     Document Type: Article

References (22)

1. Ackland S.P. Ratain M.J. Vogelzang N.J. Pharmacokinetics and pharmacodynamics of long-term continuous-infusion doxorubicin Clin Pharmacol Ther 45 1989 340 347
2. Berg S.L. Cowan K.H. Balis F.M. Pharmacokinetics of taxol and doxorubicin administered alone and in combination by continuous 72-hour infusion J Natl Cancer Inst 86 1994 143 145
3. Bressolle F. Jacquet J.M. Galtier M. Doxorubicin and doxorubicinol plasma concentrations and excretion in parotid saliva Cancer Chemother Pharmacol 30 1992 215 218
4. Bronchud M.H. Margison J.M. Howell A. Comparative pharmacokinetics of escalating doses of doxorubicin in patients with metastatic breast cancer Cancer Chemother Pharmacol 25 1990 435 439
5. Camaggi C.M. Comparsi R. Strocchi E. Epirubicin and doxorubicin comparative metabolism and pharmacokinetics: A cross-over study Cancer Chemother Pharmacol 21 1988 221 228
6. Eksborg S. Cedermark B.J. Strandler H.S. Intrahepatic and intravenous administration of Adriamycin: A comparative pharmacokinetic study in patients with malignant liver tumours Med Oncol Tumor Pharmacother 2 1985 47 54
7. Erttmann R. Erb N. Steinhoff A. Pharmacokinetics of doxorubicin in man: Dose and schedule dependence J Cancer Res Clin Oncol 114 1988 509 513
8. Garnick M.B. Ensminger W.D. Israel M. A clinical-pharmacological evaluation of hepatic arterial infusion of Adriamycin Cancer Res 39 1979 4105 4110
9. Johnson P.J. Kalayci C. Dobbs N. Pharmacokinetics and toxicity of intraarterial Adriamycin for hepatocellular carcinoma: Effect of coadministration of lipiodol J He-patol 13 1991 120 127
10. Ku Y. Fukumoto T. Iwasaki T. Clinical pilot study on high-dose intraarterial chemotherapy with direct hemoperfusion under hepatic venous isolation in patients with advanced hepatocellular carcinoma Surgery 117 1994 510 519
11. Ku Y. Saitoh M. Iwasaki T. Intraarterial infusion of high-dose Adriamycin for unresectable hepatocellular carcinoma using direct hemoperfusion under hepatic venous isolation Eur J Surg Oncol 19 1993 387 392
12. Leca F. Marchiset-Leca D. Noble A. New data on the pharmacokinetics of Adriamycin and its major metabolite, adriamycinol Eur J Drug Metab Pharmacokinet 16 1991 107 111
13. Mross K. Maessen P. van der Vijgh W.J. Pharmacokinetics and metabolism of epi-doxorubicin and doxorubicin in humans J Clin Oncol 6 1988 517 526
14. Mross K. Mayer U. Hamm K. Pharmacokinetics and metabolism of iodo-doxorub-icin and doxorubicin in humans Eur J Clin Pharmacol 39 1990 507 513
15. Preiss R. Sohr R. Kittelmann B. Investigations on the dose-dependent pharmacokinetics of adriamycin and its metabolites Int J Clin Pharmacol Ther Toxicol 27 1989 156 164
16. Raoul J.L. Heresbach D. Bretagne J.F. Chemoembolization of hepatocellular carcinomas: A study of the biodistribution and pharmacokinetics of doxorubicin Cancer 70 1992 585 590
17. Ratain M.J. Robert J. van der Vijgh W.J. Limited sampling models for doxorubicin pharmacokinetics J Clin Oncol 9 1991 871 876
18. Ravikumar T.S. Pizzorno G. Bodden W. Percutaneous hepatic vein isolation and high dose hepatic arterial infusion chemotherapy for unresectable liver tumors Clin Oncol 12 1994 2723 2736
19. Rodvold K.A. Rushing D.A. Tewksbury D.A. Doxorubicin clearance in the obese J Clin Oncol 6 1988 1321 1327
20. Rossi C. Gasparini G. Canobbio L. Doxorubicin distribution in human breast cancer Cancer Treat Rep 71 1987 1221 1226
21. Twelves C.J. Dobbs N.A. Aldhous M. Comparative pharmacokinetics of doxorubicin given by three different schedules with equal dose intensity in patients with breast cancer Cancer Chemother Pharmacol 28 1991 302 307
22. Yoshida H. Goto M. Honda A. Pharmacokinetics of doxorubicin and its active metabolite in patients with normal renal function and in patients on hemodialysis Cancer Chemother Pharmacol 33 1994 450 454